Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31683944 | 0.80 | SLC6A4 (0.50) | SLC6A4ADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL15577041 | 0.80 | SLC6A4 (0.50) | SLC6A4ADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL6956085 | 0.79 | FYN (0.38) | SLC6A4ADRA2AADRA2BADRA2CCYP19A1 | |
| SCHEMBL22344890 | 0.78 | SLC6A4 (0.46) | SLC6A4ADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL388968 | 0.78 | CYP19A1 (0.57) | DRD2DRD3HTR1ADRD4CYP19A1 | |
| SCHEMBL20359636 | 0.77 | DRD2 (0.51) | SLC6A4ADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL3964498 | 0.77 | SLC6A4 (0.42) | SLC6A4ADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL12993448 | 0.77 | SLC6A4 (0.42) | SLC6A4ADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL3090923 | 0.76 | PNMT (0.57) | SLC6A4ADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL20584776 | 0.76 | TRPM5 (0.42) | ACHECYP19A1CYP11B2TRPM5PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARM INC (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| EP-1010693-B1 | Imidazoline derivatives, preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-09-24 | — | — | EP | disclosed |
| US-6127396-A | Imidazoline compounds | ADIR ET COMPAGNIE (FR) | 2000-10-03 | — | — | US | disclosed |
| EP-1010693-A1 | Imidazoline derivatives, preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2000-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | SLC6A4 4217/4885ADRA2A 3304/4885ADRA2B 3297/4885 |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | SLC6A4 4217/4885ADRA2A 3304/4885ADRA2B 3297/4885 |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | SLC6A4 4217/4885ADRA2A 3304/4885ADRA2B 3297/4885 |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | SLC6A4 4217/4885ADRA2A 3304/4885ADRA2B 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.